DrugDashboards

Mydayis

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE · DEXTROAMPHETAMINE SULFATE 12.5 mg/1; DEXTROAMPHETAMINE SACCHARATE 12.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 12.5 mg/1; AMPHETAMINE SULFATE 12.5 mg/1 · Capsule, Extended Release · Oral · Takeda Pharmaceuticals America, Inc.

NDC 54092-0477-01 · 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $10.80 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$10.80per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$11.00per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$10.65per unitnegotiated price across 10 plans — before rebates · Jul 1, 2024

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$10.65per unit
middle half $10.63$10.65 · 10 plans · Jul 1, 2024
Est. net of rebates
$6.39–$7.98
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.

NADAC price per unit

$0$5.00$10.00$15.00Oct 2017Sep 2026$10.80
40 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$324.08
#90 count
$972.25

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$1.7M
5,485 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA022063
TE code
AB2
Approval date
Jun 20, 2017
Patents / exclusivity
8 patents, 0 exclusivities
TypeNumber / codeExpires
patent8846100Aug 24, 2029
patent8846100Aug 24, 2029
patent8846100Aug 24, 2029
patent8846100Aug 24, 2029
patent9173857May 12, 2026
patent9173857May 12, 2026
patent9173857May 12, 2026
patent9173857May 12, 2026

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE (Capsule, Extended Release)

LabelerStrengthFirst seenLast seen
Patheon Manufacturing Services LLCDEXTROAMPHETAMINE SULFATE 5 mg/1; DEXTROAMPHETAMINE SACCHARATE 5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1Jul 22, 2026Sep 2, 2026
Patheon Manufacturing Services LLCDEXTROAMPHETAMINE SULFATE 7.5 mg/1; DEXTROAMPHETAMINE SACCHARATE 7.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1Jul 22, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.DEXTROAMPHETAMINE SULFATE 9.375 mg/1; DEXTROAMPHETAMINE SACCHARATE 9.375 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 9.375 mg/1; AMPHETAMINE SULFATE 9.375 mg/1Jul 22, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.DEXTROAMPHETAMINE SULFATE 12.5 mg/1; DEXTROAMPHETAMINE SACCHARATE 12.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 12.5 mg/1; AMPHETAMINE SULFATE 12.5 mg/1Jul 22, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.DEXTROAMPHETAMINE SULFATE 3.125 mg/1; DEXTROAMPHETAMINE SACCHARATE 3.125 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1Jul 22, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.DEXTROAMPHETAMINE SULFATE 6.25 mg/1; DEXTROAMPHETAMINE SACCHARATE 6.25 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1Jul 22, 2026Sep 2, 2026
Patheon Manufacturing Services LLCAMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROAMPHETAMINE SACCHARATE 5 mg/1; DEXTROAMPHETAMINE SULFATE 5 mg/1Jul 15, 2026Jul 15, 2026
Patheon Manufacturing Services LLCAMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1; DEXTROAMPHETAMINE SACCHARATE 7.5 mg/1; DEXTROAMPHETAMINE SULFATE 7.5 mg/1Jul 15, 2026Jul 15, 2026
Takeda Pharmaceuticals America, Inc.AMPHETAMINE ASPARTATE MONOHYDRATE 12.5 mg/1; AMPHETAMINE SULFATE 12.5 mg/1; DEXTROAMPHETAMINE SACCHARATE 12.5 mg/1; DEXTROAMPHETAMINE SULFATE 12.5 mg/1Jul 15, 2026Jul 15, 2026
Takeda Pharmaceuticals America, Inc.AMPHETAMINE ASPARTATE MONOHYDRATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1; DEXTROAMPHETAMINE SACCHARATE 3.125 mg/1; DEXTROAMPHETAMINE SULFATE 3.125 mg/1Jul 15, 2026Jul 15, 2026
Takeda Pharmaceuticals America, Inc.AMPHETAMINE ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; DEXTROAMPHETAMINE SACCHARATE 6.25 mg/1; DEXTROAMPHETAMINE SULFATE 6.25 mg/1Jul 15, 2026Jul 15, 2026
Takeda Pharmaceuticals America, Inc.AMPHETAMINE ASPARTATE MONOHYDRATE 9.375 mg/1; AMPHETAMINE SULFATE 9.375 mg/1; DEXTROAMPHETAMINE SACCHARATE 9.375 mg/1; DEXTROAMPHETAMINE SULFATE 9.375 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Mydayis — NDC 54092-0477-01," retrieved September 3, 2026, https://drugdashboards.com/drug/54092047701.

Free to cite with attribution — see how the data is put together.